Company / Working Capital
NewAmsterdam Pharma Co N.V. Working Capital History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$589.9M
FY2025
5-year range
$296.9M / $756.5M
FY2022-FY2025
Trend
-22.0%
vs FY2024
Sector context
#78 of 214
Health Care
What the data says
At $590M, NewAmsterdam Pharma Co N.V.'s working capital ranks #78 of 214 in the Health Care sector. Improved from $297M to $590M over the past 2 years.
Based on SEC 10-K filings.
$590M in FY2025 with a 3-year CAGR of +10.1%.
Improved from $297M to $590M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +10.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#78 of 214 in Health CareTop 36% of 214This company $589.9M Sector average $955.5M
▼
-38.3% below sector average
Key checks
Key Insights
- 3-year CAGR of +10.1%, indicating consistent growth.
- In FY2025, working capital decreased 22.0% year-over-year.
- Ranks #78 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $589.9M | -22.0% |
| FY2024 | $756.5M | +154.8% |
| FY2023 | $296.9M | -32.8% |
| FY2022 | $441.9M | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026